MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL
Final 7-year follow-up findings from the MURANO study were revealed at this EHA 23’ congress. In this MEDtalk, professor of Translational Hematology, Arnon Kater, presents the results indicating meaningful progression-free survival of patients with relapsed/refractory chronic lymphatic leukemia (R/R CLL) treated with venetolax-rituximab (VenR).
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
